Dr. Jennifer Bath, president and CEO of MindWalk (NASDAQ: HYFT), will join a virtual panel at Jones AI Day on Monday, June 15, 2026, at 12:00 p.m. ET. She will discuss alongside executives from Absci (NASDAQ: ABSI) and a major AI compute provider how combining biological context with high-performance compute can reduce prolonged screening timelines and address historically undruggable targets.
The biological context layer
MindWalk operates as a biology company that built artificial intelligence on 25 years of wet-lab expertise. Its proprietary HYFT technology underpins ReefIQ, a biological context layer that enriches data at ingestion. This system connects information across a dynamic knowledge representation of 660 million biological patterns and 25 billion relationships. The LensAI platform functions as the reasoning and application layer, demonstrating how AI for Healthcare can operate on structured biological context rather than statistical correlation.
Preventing AI hallucinations
Because its predictions rely on evolutionary constraints rather than statistical correlation, the architecture aims to prevent AI models and autonomous agents from hallucinating in high-consequence drug discovery workflows. Dr. Bath plans to argue that the durable asset in biological AI is the enriched context layer, not any individual model.
"The hardest problem in drug discovery was never a shortage of compute or models - it's that biological data arrives fragmented, and a model reasoning over fragments will confidently get it wrong," Dr. Bath said. "Our work grounds that reasoning in what evolution has already constrained, so the biology is connected and real before a model ever acts on it."
Panel logistics and participants
Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail will moderate the session, titled "Partnering to Power the New Era of Drug Discovery." The panel also features Sean McClain, founder and CEO of Absci, alongside senior life-science strategy leadership from the unnamed compute provider, illustrating the cross-functional collaboration required for AI for Executives & Strategy in regulated environments. Registration remains open to institutional investors through Jones, with RSVPs directed to Yuki Gonzalez.
Why this matters for executives and strategy leaders
Leaders evaluating AI investments in life sciences must look beyond compute capacity and model size. The competitive advantage lies in proprietary, high-fidelity biological context layers that prevent costly errors in regulated workflows. Companies that secure access to these enriched data environments will dictate the pace of target discovery and candidate diligence, while those relying solely on generic models risk producing confidently incorrect outputs.
Source: MindWalk Holdings Corp via Business Wire
Your membership also unlocks:
